title: Predictors of intracranial hemorrhage with fibrinolytic therapy in unselected community patients: a report from the FASTRAK II project.
abstract: BACKGROUND
  Patients at high risk for intracranial hemorrhage (ICH) are generally excluded from thrombolytic trials. Because the frequency and predictors of ICH reported from these studies may not be widely applicable, we sought to examine this matter further in unselected patients with acute myocardial infarction in the community.
  
  
  METHODS
  FASTRAK II is a prospective ongoing registry of acute coronary syndromes involving 111 Canadian hospitals. Trained medical personnel recorded admission, treatment, and discharge data on patients admitted with acute coronary syndromes.
  
  
  RESULTS
  From January 1, 1998, to December 31, 2000, 12,739 patients received fibrinolytic therapy for acute myocardial infarction. Of these, 146 patients (1.15%) sustained strokes and 82 patients (0.65%) had an ICH. Advanced age, female sex, history of cerebrovascular event, and systolic hypertension on arrival (systolic blood pressure >160 mm Hg) were identified with a multivariate logistic regression model to be important independent risks factors for ICH. Patients receiving streptokinase had a lower risk of ICH. Among the patients at high risk for ICH, the ICH rates remained low, ranging from 0.7% to 1.8%.
  
  
  CONCLUSIONS
  ICH is an infrequent event after fibrinolytic therapy in ST-elevation MI; this low rate supports broad penetration of this therapy. Simple clinical characteristics are useful in predicting the risk of ICH and allow a clinician to individualize the risk-benefit assessment of this therapy.
authors.affiliation: Montreal General Hospital, McGill Health University Center, Montreal, Quebec, Canada. thao.huynh@muhc.mcgill.ca
authors.forename: Thao
authors.initials: T
authors.lastname: Huynh
authors.forename: Jafna L
authors.initials: JL
authors.lastname: Cox
authors.forename: David
authors.initials: D
authors.lastname: Massel
authors.forename: Cheryl
authors.initials: C
authors.lastname: Davies
authors.forename: Joseph
authors.initials: J
authors.lastname: Hilbe
authors.forename: Wayne
authors.initials: W
authors.lastname: Warnica
authors.forename: Paul A
authors.initials: PA
authors.lastname: Daly
mesh_terms: D000368:Aged; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000150:complications; D020300:Intracranial Hemorrhages / Q000139:chemically induced*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy*; D011379:Prognosis; D011446:Prospective Studies; D012042:Registries; D012307:Risk Factors; D012737:Sex Factors; D013300:Streptokinase / Q000009:adverse effects / Q000627:therapeutic use; D020521:Stroke / Q000139:chemically induced; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D013300:Streptokinase; D010959:Tissue Plasminogen Activator